Work Package 2 Phase 1 - Beverages Study

Inclusion Criteria: * Age: 18-60 years. * BMI: 25 to 35 kg/m2. * For women: Use of contraceptive methods or not planning to become pregnant for the duration of the study. * Regular consumption of sugar-containing foods and willing to consume artificially-sweetened beverages (a score of ≥ 5 on the short sFFQ Part 1a and answer Yes to all questions in Part 2). * Able to participate on the visit days/CIDs during normal working hours. * Healthy as determined from the self-reported medical history or when a clinical condition exists, when this is considered to be irrelevant (i.e. not influencing study outcomes) for the study by the study medical doctor. * Consuming breakfast regularly (at least 5 days per week). * Liking of the study foods defined by a response of Yes for each of the breakfast foods during the pre-screening interview and a score of 40 % or above on the Liking VAS for the control beverage. * Able to understand and be willing to sign the informed consent form, and to follow all the study procedures and requirements. Exclusion Criteria: * Blood donation \< 3 month prior to study. * Deficient nutrition or hydration status as identified from the pre-screening/screening session (i.e. absence of disease including anaemia, BMI \>18 kg/m2, or other criteria as determined by the study doctor). * Food allergy, intolerance, restriction or avoidance of any of the study foods (e.g. veganism) or history of anaphylactic reaction to any food. * Likelihood for disordered eating defined as a score of 20 or more on the EAT-26 test. * Currently dieting to lose weight or having been on weight cycles (i.e. repeatedly lost and re-gained weight) in the last 3 months. * Smoking. * Binge drinking i.e. consuming \>14 units of alcohol per week in women or \>21 units/week in men less than 4 days apart. * Performing \>10 h of intense physical activity per week. * Continuous night or late shift work (ending later than 11 pm on a permanent basis). Rotational shift work allowed if can attend on days that do not follow a late/night shift. * Self-reported use of drugs of abuse within the previous 12 months. * For women: Pregnancy, lactation. * Persons who do not have access to either (mobile) phone or internet (this is necessary when being contacted by the study personnel during the study). * Insufficient communication in the national language. * Proven or suspected inability, physically or mentally, to comply with the procedures required by the study protocol as evaluated by the daily study manager, site-PI, PI or clinical responsible. This includes volunteers for which insufficient collaboration may be foreseen. * Subject's general condition contraindicates continuing in the study as evaluated by the daily study manager, site-PI, PI or clinical responsible. * Simultaneous participation in other relevant clinical intervention studies. * Previous university or college training related to eating behaviour research. * Medical conditions as known by the person: * Self-reported eating disorders. * Diagnosed anaemia. * Diagnosed diabetes mellitus. * Abnormal gastro-intestinal (G.I) function or structure such as malformation, angiodysplasia, active peptic ulcer. * Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption. * History of G.I. surgery with permanent effect (i.e. surgical treatment of obesity). * Medical history of cardio-vascular disease (e.g. current angina; myocardial infarction or stroke within the past 6 months; heart failure; symptomatic peripheral vascular disease). * Significant liver disease, e.g. cirrhosis (fatty liver disease allowed). * Malignancy which is currently active or in remission for less than five years after last treatment (local basal and squamous cell skin cancer allowed). * Thyroid diseases, except those on Levothyroxine treatment of hypothyroidism if the person has been on a stable dose for at least 3 months. * Psychiatric illness (e.g. major depression, bipolar disorders). * Medication: * Use currently or within the previous 3 months of prescription or over the counter medication that has the potential of affecting appetite, satiety or body weight incl. food supplements. Except: low dose antidepressants if they, in the judgement of the daily study manager, site-PI, PI or clinical responsible, do not affect weight or following the study protocol. Levothyroxine for treatment of hypothyroidism is allowed if the person has been on a stable dose for at least 3 months. • Cholesterol lowering medication, if the dose has changed during the last 3 months (i.e. the medication is allowed if the participant has been on a stable dose for at least 3 months).